Beta Bionics, Inc. Common Stock vs. Stryker Corporation
Beta Bionics, Inc. Common Stock (BBNX) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| BBNX | SYK | |
|---|---|---|
| Market Cap | $997.87 million | $107.98 billion |
| Revenue (TTM) | — | $25.84 billion |
| Net Income (TTM) | — | $3.73 billion |
SYK leads on 1 of 1 size & scale factors.
Valuation
| BBNX | SYK | |
|---|---|---|
| P/E Ratio | — | 29.51 |
| Price / Book | 3.89 | 4.50 |
| Price / Sales | — | 4.18 |
BBNX leads on 1 of 1 valuation factors.
Profitability
| BBNX | SYK | |
|---|---|---|
| Net Margin | — | 14.43% |
| Return on Equity | — | 15.55% |
BBNX and SYK split the profitability factors evenly.
Dividend
| BBNX | SYK | |
|---|---|---|
| Dividend Yield | — | 1.24% |
| Payout Ratio | — | 36.48 |
BBNX and SYK split the dividend factors evenly.
Risk & Sentiment
| BBNX | SYK | |
|---|---|---|
| Short Interest | 0.47% | 1.53% |
BBNX leads on 1 of 1 risk & sentiment factors.
Dig deeper: BBNX overview, BBNX financials, SYK overview, SYK financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.